SCHEMBL7003365

SCHEMBL7003365

Nc1cccc2c1c(-c1ccccc1)nn2Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
ADORA1 P30542 2/20 0.44
GAA P10253 2/20 0.44
POLB P06746 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
LMNA P02545 3/20 0.43
HTT P42858 2/20 0.43
MAPT P10636 1/20 0.43
PIK3CD O00329 1/20 0.43
PIK3CA P42336 1/20 0.43
PIK3CB P42338 1/20 0.43
PIK3CG P48736 1/20 0.43
PRKDC P78527 1/20 0.43
CYP1A2 P05177 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7002366 0.84 ESR1 (0.52) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL9937958 0.81 KDM4E (0.56) SMN1; SMN2ADORA1GAAPOLBMEN1
SCHEMBL2047746 0.81 KDM4E (0.42) SMN1; SMN2GAAPOLBMEN1KMT2A
SCHEMBL2048520 0.78 KDM4E (0.43) SMN1; SMN2GAAPOLBSCN8APDE5A
SCHEMBL7000693 0.78 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2PDE4APDE4BPDE4C
SCHEMBL7001959 0.77 SRC (0.56) SMN1; SMN2GAAMEN1KMT2ALMNA
SCHEMBL7000617 0.77 PDE4A (0.44) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL3621787 0.76 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2PDE4APDE4BPDE4C
SCHEMBL7006143 0.76 MAPK13 (0.47) ALDH1A1GAAPOLBMEN1KMT2A
SCHEMBL2048233 0.76 ADORA1 (0.42) ADORA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140938-B1 HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF UNIV PRINCETON (US) 2003-08-27 EP disclosed
EP-1321467-A2 High affinity inhibitors for target validation and uses thereof Princeton University (US) 2003-06-25 EP disclosed
US-20030073218-A1 High affinity inhibitors for target validation and uses thereof PRINCETON UNIVERSITY 2003-04-17 US disclosed
US-6383790-B1 PYRAZOLO(3,4-D)PYRIMIDINE BASED COMPOUND; ANTICARCINOGENIC AGENTS; ANTITUMOR AGENTS PRINCETON UNIVERSITY 2002-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073218-A1 High affinity inhibitors for target validation and uses thereof SRC, MARCKS, TEC ALDH1A1 4694/4885SMN1; SMN2 4306/4885PDE4A 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.